ValiRx plc (LON:VAL – Get Free Report) shares dropped 3.8% on Monday . The company traded as low as GBX 1.55 ($0.02) and last traded at GBX 1.55 ($0.02). Approximately 81,907 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 1,074,924 shares. The stock had previously closed at GBX 1.61 ($0.02).
ValiRx Stock Performance
The firm has a market cap of £2.12 million, a PE ratio of -80.00 and a beta of 0.59. The company has a quick ratio of 1.27, a current ratio of 6.65 and a debt-to-equity ratio of 0.49. The stock’s fifty day simple moving average is GBX 1.79 and its two-hundred day simple moving average is GBX 2.48.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Read More
- Five stocks we like better than ValiRx
- Best Stocks Under $5.00
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- ETF Screener: Uses and Step-by-Step Guide
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- What is the Nikkei 225 index?
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
